Treatment of BRAF-Mutated Metastatic Melanoma: Immunotherapy or Target Therapy?

Metastatic melanoma has been associated with a poor prognosis, with overall survival rates at 5 years of 10%. Until 2011, the only treatments available for metastatic melanoma were chemotherapy and immunotherapy with interleukin-2. The more in-depth knowledge about the molecular biology of melanoma...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Sofia Rodrigues (Author), Ana Brinca (Author)
Format: Book
Published: Sociedade Portuguesa de Dermatologia e Venereologia, 2021-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available